Published Data in Metastatic Pancreatic Cancer

Most patients have locally advanced and/or metastatic pancreatic cancer, resulting in a dismal 5 year survival rate of <5%. In patients with liver metastases from primary cancer of the pancreas, encouraging results on the use of SIR-Spheres® Y-90 resin microspheres as first-line therapy for treatment-refractory disease have been obtained from prospective and retrospective studies.2,3

In one study, median survival was 5.5 months but considerably longer (13.6 months) in the cohort of patients with resected primary tumours.2 The authors concluded that the combination of SIR-Spheres Y-90 resin microspheres and 5FU appears effective in controlling metastases from pancreatic cancer, with extra-hepatic progression and resection of the primary tumour dictating survival.

When used as salvage therapy in treatment-refractory metastatic pancreatic cancer, SIR-Spheres Y-90 resin microspheres may have the potential to prolong survival even in patients with progressive disease.4,5

1  Jemal A et al. 2010. CA Cancer J Clin 2010; 60: 277-300.
2  Gibbs P et al. BMC Cancer 2015; 15: 802.
3  Michl M et al. Oncology 2014; 86: 24-32.
4  Lo G et al. J Vasc Interv Radiol 2014: 25:  811.e823-824.
5  Kim AY et al.  J Vasc Interv Radiol 2015; 26: e76.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage